US approves first drug for brain symptoms of type 3 Gaucher disease

The US Food and Drug Administration has approved the first medicine to treat the neurological symptoms of type 3 Gaucher disease, a rare inherited condition. Sanofi’s once-daily tablet, Infilbray (venglustat), is approved for adults and children weighing at least 15 kilograms.

The disease prevents the body from properly breaking down certain fatty substances. Their buildup in the brain can progressively affect balance, coordination, memory and thinking. Existing therapies could treat symptoms elsewhere in the body, but not these neurological effects. Infilbray crosses the protective barrier between the bloodstream and brain to reduce that buildup.

The approval rests on a trial involving 43 people aged 12 and older whose symptoms outside the nervous system had already been stabilized with enzyme replacement therapy. After 52 weeks, those taking Infilbray improved on a combined measure of coordination and thinking skills compared with those receiving enzyme replacement infusions.

The medicine carries important risks. Common side effects include digestive problems and mood changes, and suicidal thoughts and behavior have been reported. Animal studies also identified potential risks to fetal development and possible clouding of vision in younger patients. Follow-up research is continuing.

Sanofi says the medicine is also under regulatory review in the EU and Japan.

Sources

  1. MedPage TodayFDA Approves First Treatment for Neurologic Symptoms of Type 3 Gaucher Disease
  2. www.fda.govFDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease
  3. www.sanofi.comPress Release: Sanofi’s Infilbray approved in the US as the first medicine to treat neurological manifestations of Type 3 Gaucher disease

Reporting notes

Where this came from

FDA

FDA is the direct source for the regulatory decision, patient eligibility and its assessment of the 43-patient study. MedPage Today relays that announcement in a clinically focused account rather than supplying a separate trial or independent efficacy assessment.

Sanofi

Sanofi's announcement is the material origin for the detailed sponsor-reported LEAP2MONO results, including the p=0.0137 composite-endpoint finding. MedPage Today incorporates those details into its medical coverage; this is shared underlying evidence, not independent replication.

US approves first drug for brain symptoms of type 3 Gaucher disease